Sagimet Biosciences Inc.(SGMT)
$10.75—Stale · unknown old
Sagimet Biosciences Inc.(SGMT)
NASDAQ • Last print unknown ago
$10.75—Stale · unknown old
Q4 2026 EPS Estimate
$-0.25
Nov 12, 2026 · Reports before open
Revenue Estimate
$166,667
FY2030E EPS$0.80
Analyst Sentiment
Wall St. Consensus
Buy7 analysts·Limited coverage
71
Score
6 Buy (86%)1 Hold (14%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
686%
Hold
114%
Sell
00%
Strong Sell
00%
Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.
Price Target Expectations
Bear
$6.00
-44.2%
Consensus
$7.00
-34.9%
Bull
$8.00
-25.6%
12-Month Target Range7 analysts
$6.00$7.00$8.00
Current $10.75Consensus
Current Price
$10.75
Above Consensus
$3.75
Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.
Earnings & Revenue Estimates
Forward Growth Estimates (YoY)
FY2027
Rev+6673.86%
EPS—
FY2028
Rev+223.95%
EPS—
FY2029
Rev+399.95%
EPS—
Raw consensus estimates (low / average / high) from covering analysts.
Annual
| Metric | FY2026E | FY2027E | FY2028E | FY2029E | FY2030E |
|---|---|---|---|---|---|
| Revenue Avg | $111,111 | $8M | $24M | $122M | $301M |
| Low | $111,111 | $8M | $24M | $122M | $301M |
| High | $111,111 | $8M | $24M | $122M | $301M |
| EBITDA Avg | $66,666 | $5M | $15M | $73M | $180M |
| Low | $66,666 | $5M | $15M | $73M | $180M |
| High | $66,666 | $5M | $15M | $73M | $180M |
| EBIT Avg | $66,666 | $5M | $15M | $73M | $180M |
| Low | $66,666 | $5M | $15M | $73M | $180M |
| High | $66,666 | $5M | $15M | $73M | $180M |
| Net Income Avg | $-39M | $-46M | $-58M | $-23M | $26M |
| Low | $-47M | $-68M | $-88M | $-23M | $26M |
| High | $-30M | $-23M | $-28M | $-23M | $26M |
| EPS Avg | $-1.17 | $-1.39 | $-1.68 | $-0.71 | $0.80 |
| Low | $-1.44 | $-2.10 | $-2.73 | $-0.71 | $0.80 |
| High | $-0.94 | $-0.73 | $-0.88 | $-0.71 | $0.80 |
| Analysts (Rev / EPS) | 6 / 7 | 6 / 7 | 8 / 8 | 6 / 5 | 6 / 5 |
Quarterly
| Metric | Q3 2026 | Q4 2026 | Q1 2027 | Q2 2027 | Q3 2027 | Q4 2027 |
|---|---|---|---|---|---|---|
| Revenue Avg | $166,667 | $166,667 | $333,333 | $333,333 | $333,333 | $333,333 |
| Low | $166,667 | $166,667 | $333,333 | $333,333 | $333,333 | $333,333 |
| High | $166,667 | $166,667 | $333,333 | $333,333 | $333,333 | $333,333 |
| EBITDA Avg | $100,000 | $100,000 | $199,999 | $199,999 | $199,999 | $199,999 |
| Low | $100,000 | $100,000 | $199,999 | $199,999 | $199,999 | $199,999 |
| High | $100,000 | $100,000 | $199,999 | $199,999 | $199,999 | $199,999 |
| EBIT Avg | $100,000 | $100,000 | $199,999 | $199,999 | $199,999 | $199,999 |
| Low | $100,000 | $100,000 | $199,999 | $199,999 | $199,999 | $199,999 |
| High | $100,000 | $100,000 | $199,999 | $199,999 | $199,999 | $199,999 |
| Net Income Avg | $-14M | $-16M | $-18M | $-19M | $-21M | $-20M |
| Low | $-15M | $-18M | $-18M | $-19M | $-21M | $-20M |
| High | $-11M | $-12M | $-18M | $-19M | $-21M | $-20M |
| EPS Avg | $-0.26 | $-0.30 | $-0.33 | $-0.36 | $-0.39 | $-0.37 |
| Low | $-0.29 | $-0.33 | $-0.33 | $-0.36 | $-0.39 | $-0.37 |
| High | $-0.20 | $-0.22 | $-0.33 | $-0.36 | $-0.39 | $-0.37 |
| Analysts (Rev / EPS) | 4 / 6 | 5 / 6 | 4 / 2 | 5 / 2 | 4 / 2 | 5 / 2 |